Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition - Investing.com
Inhibrx Biosciences, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $104.01
-7.5% in 3d after detection
Post-detection moves
1h
—
1d
+0.5%
3d
-7.5%
7d
-5.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS